Tech Company Financing Transactions
Inhibrx Funding Round
On 5/23/2019, Inhibrx secured $40 million in investment from Alexandria Venture Investments, ArrowMark Partners and Lilly Asia Ventures.
Transaction Overview
Company Name
Announced On
5/23/2019
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This new investment, coupled with our current investor support, provides us with additional capital to advance our pipeline, including our three clinical-stage programs with two additional programs expected to enter the clinic this year, and our proprietary sdAb platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11025 North Torrey Pines Rd. 200
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Inhibrx (Nasdaq: INBX), our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer, infectious disease and orphan diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Lappe
Chief Medical Officer
Klaus Wagner
Chief Scientific Officer
Brendan Eckelman
Vice President
Analeah Heidt
VP - Finance
Kelly Deck
VP - Operations
Ashraf Amanullah
VP - R & D
Quinn Deveraux
VP - R & D
John Timmer
Browse more venture capital transactions:
Prev: 5/23/2019: Artemis venture capital transaction
Next: 5/23/2019: Solugen venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs